Cargando…
Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai
BACKGROUND: Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy of SXSM...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902583/ https://www.ncbi.nlm.nih.gov/pubmed/31822281 http://dx.doi.org/10.1186/s12906-019-2769-0 |
_version_ | 1783477701204508672 |
---|---|
author | Gao, Jiaming Wang, Taiyi Yao, Xi Xie, Weiwei Shi, Xianru He, Shuang Zhao, Tao Wang, Chunhua Zhu, Yan |
author_facet | Gao, Jiaming Wang, Taiyi Yao, Xi Xie, Weiwei Shi, Xianru He, Shuang Zhao, Tao Wang, Chunhua Zhu, Yan |
author_sort | Gao, Jiaming |
collection | PubMed |
description | BACKGROUND: Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy of SXSM on bradycardia and to identify the possible active components and their pharmacological targets for this action. METHODS: A literature-based meta-analysis was performed to evaluate the clinical efficacy of SXSM on bradycardia, which was confirmed by a rat ex vivo cardiac model. Network pharmacology analysis was then conducted to reveal the potential targets of SXSM active components and their anti-arrhythmia mechanisms. Finally, the identified drug-target interaction was confirmed by immunofluorescence assay in cardiomyocyte. RESULTS: Meta-analysis of the available clinical study data shows that Shenxian-Shengmai Oral Liquid has a favorable effect for bradycardia. In an ex vivo bradycardia model of rat heart, SXSM restored heart rate by affecting Heart rate variability (HRV) which is associated with autonomic nervous system activity. A drug-target-pathway network analysis connecting SXSM components with arrhythmia suggested that a prominent anti-arrhythmia mechanisms of SXSM was via β1-adrenergic signaling pathway, which was subsequently validated by immunofluorescence assay showing that SXSM indeed increased the expression of ADRB1 in cultured cardiomyocytes. CONCLUSION: By combining approaches of clinical evidence mining, experimental model confirmation, network pharmacology analyses and molecular mechanistic validation, we show that SXSM is an effective treatment for bradycardia and it involves multiple component interacting via multiple pathways, among which is the critical β1-adrenergic receptor upregulation. Our integrative approach could be applied to other multi-component traditional Chinese medicine investigation where ample clinical data are accumulated but advanced mechanistic studies are lacking. |
format | Online Article Text |
id | pubmed-6902583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69025832019-12-11 Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai Gao, Jiaming Wang, Taiyi Yao, Xi Xie, Weiwei Shi, Xianru He, Shuang Zhao, Tao Wang, Chunhua Zhu, Yan BMC Complement Altern Med Research Article BACKGROUND: Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy of SXSM on bradycardia and to identify the possible active components and their pharmacological targets for this action. METHODS: A literature-based meta-analysis was performed to evaluate the clinical efficacy of SXSM on bradycardia, which was confirmed by a rat ex vivo cardiac model. Network pharmacology analysis was then conducted to reveal the potential targets of SXSM active components and their anti-arrhythmia mechanisms. Finally, the identified drug-target interaction was confirmed by immunofluorescence assay in cardiomyocyte. RESULTS: Meta-analysis of the available clinical study data shows that Shenxian-Shengmai Oral Liquid has a favorable effect for bradycardia. In an ex vivo bradycardia model of rat heart, SXSM restored heart rate by affecting Heart rate variability (HRV) which is associated with autonomic nervous system activity. A drug-target-pathway network analysis connecting SXSM components with arrhythmia suggested that a prominent anti-arrhythmia mechanisms of SXSM was via β1-adrenergic signaling pathway, which was subsequently validated by immunofluorescence assay showing that SXSM indeed increased the expression of ADRB1 in cultured cardiomyocytes. CONCLUSION: By combining approaches of clinical evidence mining, experimental model confirmation, network pharmacology analyses and molecular mechanistic validation, we show that SXSM is an effective treatment for bradycardia and it involves multiple component interacting via multiple pathways, among which is the critical β1-adrenergic receptor upregulation. Our integrative approach could be applied to other multi-component traditional Chinese medicine investigation where ample clinical data are accumulated but advanced mechanistic studies are lacking. BioMed Central 2019-12-10 /pmc/articles/PMC6902583/ /pubmed/31822281 http://dx.doi.org/10.1186/s12906-019-2769-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Gao, Jiaming Wang, Taiyi Yao, Xi Xie, Weiwei Shi, Xianru He, Shuang Zhao, Tao Wang, Chunhua Zhu, Yan Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai |
title | Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai |
title_full | Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai |
title_fullStr | Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai |
title_full_unstemmed | Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai |
title_short | Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai |
title_sort | clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by shenxian-shengmai |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902583/ https://www.ncbi.nlm.nih.gov/pubmed/31822281 http://dx.doi.org/10.1186/s12906-019-2769-0 |
work_keys_str_mv | AT gaojiaming clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai AT wangtaiyi clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai AT yaoxi clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai AT xieweiwei clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai AT shixianru clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai AT heshuang clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai AT zhaotao clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai AT wangchunhua clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai AT zhuyan clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai |